GlassScriptPhysician profile
Mark Yarchoan
NPI 1962761080
$88,924.88
in general payments reported to CMS, 2019-2025
14 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,972 · 2020: $16K · 2021: $9,834 · 2022: $8,824 · 2023: $12K · 2024: $12K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $34K · Travel and Lodging: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,640 · Food and Beverage: $1,937 · Grant: $1,800 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $34,103.14 |
| Travel and Lodging | $10,411.71 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,640.00 |
| Food and Beverage | $1,936.98 |
| Grant | $1,800.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25,342.74 | 2020-2025 | Imfinzi, Enhertu |
| Genentech, INC. | $17,359.27 | 2019-2025 | Tecentriq |
| Exelixis INC. | $13,311.25 | 2019-2023 | Cabometyx |
| F. Hoffmann-La Roche Ag | $10,230.54 | 2021-2025 | Tecentriq |
| Genentech USA, INC. | $7,765.25 | 2020-2024 | Tecentriq |
| Eisai INC. | $6,825.46 | 2019-2020 | |
| Incyte Corporation | $4,470.64 | 2022-2025 | Pemazyre, Pemazyre |
| Eisai Co., LTD. | $2,040.00 | 2021 | |
| Abbvie INC. | $1,037.96 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.80 | 2019-2020 | |
| Modernatx, INC. | $98.30 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $47.77 | 2022 | |
| Boston Scientific Corporation | $37.90 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yarchoan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.